MedPath

FORMOSA PHARMACEUTICALS, INC.

๐Ÿ‡น๐Ÿ‡ผTaiwan
Ownership
Public
Employees
-
Market Cap
-
Website
http://www.formosapharma.com

Clinical Trials

3

Active:0
Completed:3

Trial Phases

2 Phases

Phase 2:1
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)โ€ข Click on a phase to view related trials

Phase 3
2 (66.7%)
Phase 2
1 (33.3%)

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

Phase 3
Completed
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
Drug: APP13007, 0.05%
Drug: Matching Vehicle Placebo for APP13007, 0.05%
First Posted Date
2021-03-23
Last Posted Date
2023-07-25
Lead Sponsor
Formosa Pharmaceuticals, Inc.
Target Recruit Count
370
Registration Number
NCT04810962
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Arizona Eye Center, Chandler, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Carrot Eye Center, Mesa, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States

and more 28 locations

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery

Phase 3
Completed
Conditions
Ocular Inflammation and Pain
Interventions
Drug: Matching Vehicle Placebo for APP13007, 0.05%
Drug: APP13007, 0.05%
First Posted Date
2021-02-05
Last Posted Date
2023-07-20
Lead Sponsor
Formosa Pharmaceuticals, Inc.
Target Recruit Count
378
Registration Number
NCT04739709
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Schwartz Laser Eye Center, Scottsdale, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

Global Research Management, Glendale, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Inland Eye Specialists, Hemet, California, United States

and more 32 locations

A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery

Phase 2
Completed
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
Drug: APP13007 Placebo, 0.05%
Drug: APP13007, 0.05%
Drug: APP13007, 0.1%
Drug: APP13007 Placebo, 0.1%
First Posted Date
2019-09-13
Last Posted Date
2023-06-27
Lead Sponsor
Formosa Pharmaceuticals, Inc.
Target Recruit Count
165
Registration Number
NCT04089735
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States

๐Ÿ‡บ๐Ÿ‡ธ

United Medical Research Institute, Inglewood, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Martel Eye Medical Group, Rancho Cordova, California, United States

and more 6 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

ยฉ 2025 MedPath, Inc. All rights reserved.